Format

Send to

Choose Destination
JAMA Oncol. 2015 Sep;1(6):836-8. doi: 10.1001/jamaoncol.2015.0736.

Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis.

Author information

1
Department of Pediatric Hematology and Oncology, Trousseau Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France Trousseau Hospital, Paris, France.
2
Department of Pediatric Hematology and Oncology, Felix Guyon Hospital, Saint-Denis Réunion, France.
3
Pathology Department, Ambroise Paré Hospital, APHP, Boulogne, France.
4
Department of Pharmacology and Toxicology, Raymond Poincaré Hospital, APHP, Garches, France.
5
Department of Internal Medicine & French Reference Center for Rare Auto-immune & Systemic Diseases, Pitié-Salpêtrière Hospital, APHP, Paris, France.
PMID:
26180941
DOI:
10.1001/jamaoncol.2015.0736
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center